Discussion stirs around Evolent Health, Inc. (NYSE:EVH) this week; here is what analysts are saying.

Evolent Health, Inc. (NYSE:EVH) Logo

Evolent Health, Inc. (NYSE:EVH) Ratings Coverage

Among 7 analysts covering Evolent Health (NYSE:EVH), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Evolent Health had 20 analyst reports since February 19, 2019 according to SRatingsIntel. Cantor Fitzgerald maintained Evolent Health, Inc. (NYSE:EVH) on Tuesday, February 26 with “Buy” rating. The stock has “Buy” rating by Piper Jaffray on Wednesday, February 27. Robert W. Baird maintained it with “Buy” rating and $25 target in Thursday, March 21 report. Oppenheimer maintained Evolent Health, Inc. (NYSE:EVH) on Monday, February 25 with “Buy” rating. The firm has “Buy” rating given on Wednesday, February 27 by Canaccord Genuity. The stock of Evolent Health, Inc. (NYSE:EVH) earned “Buy” rating by Citigroup on Wednesday, February 27. The stock of Evolent Health, Inc. (NYSE:EVH) earned “Buy” rating by Jefferies on Wednesday, February 27. Robert W. Baird maintained the shares of EVH in report on Friday, February 22 with “Buy” rating. The rating was maintained by KeyBanc Capital Markets on Monday, March 4 with “Overweight”. The firm has “Buy” rating given on Thursday, March 21 by Cantor Fitzgerald. Below is a list of Evolent Health, Inc. (NYSE:EVH) latest ratings and price target changes.

08/05/2019 Broker: BidaskScore Rating: Hold Upgrade
24/04/2019 Broker: BidaskScore Rating: Sell Upgrade
22/03/2019 Broker: BidaskScore Rating: Sell Upgrade
21/03/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $20 Maintain
21/03/2019 Broker: Robert W. Baird Rating: Buy New Target: $25 Maintain
19/03/2019 Broker: Oppenheimer Rating: Buy Maintain
14/03/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $20 Maintain
04/03/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $20 Maintain
04/03/2019 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $32 New Target: $20 Maintain
02/03/2019 Broker: BidaskScore Rating: Sell Downgrade

The stock increased 1.94% or $0.14 during the last trading session, reaching $7.36. About 1.02 million shares traded. Evolent Health, Inc. (NYSE:EVH) has declined 24.76% since July 14, 2018 and is downtrending. It has underperformed by 29.19% the S&P500.

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company has market cap of $620.52 million. It operates as a managed services firm that supports integrated health systems in migration toward value care and population health management. It currently has negative earnings. The companyÂ’s services include providing clients with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services.

More notable recent Evolent Health, Inc. (NYSE:EVH) news were published by: Finance.Yahoo.com which released: “Evolent Health (EVH) Reports Q1 Loss, Tops Revenue Estimates – Yahoo Finance” on May 07, 2019, also Prnewswire.com with their article: “Evolent Health to Host Investor and Analyst Day on May 30, 2019 – PRNewswire” published on May 13, 2019, Prnewswire.com published: “Evolent Health and SOMOS IPA Aim to Provide Physician-Driven Medicaid Managed Care through New York Innovator Program – PR Newswire” on November 06, 2018. More interesting news about Evolent Health, Inc. (NYSE:EVH) were released by: Bizjournals.com and their article: “Evolent Health stock falls on bigger loss, new stock offering – Washington Business Journal” published on August 08, 2017 as well as Streetinsider.com‘s news article titled: “Evolent Health (EVH) Reports Acquisition of New Century Health for up to $217M – StreetInsider.com” with publication date: September 12, 2018.

Evolent Health, Inc. (NYSE:EVH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.